StemCell Institute Inc.
Stock Price Chart
2026/10/01 19:14 UpdatedPrice Trend
2026/10/01 19:14 UpdatedPrice & Trading Details
2026/10/01 19:14 UpdatedPRICE
TRADING
Shareholder Composition
Updated 2026/10/01Dividend History
Updated 2026/09/27| Year | Dividend | Change |
|---|---|---|
| 2024 | ¥25 | - |
Financial Performance
2026/09/27 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥2,091M | ¥2,481M | ¥2,679M | ¥2,811M |
| Gross Profit | ¥1,336M | ¥1,576M | ¥1,692M | ¥1,712M |
| Operating Income | ¥298M | ¥414M | ¥419M | ¥203M |
| Pretax Income | ¥298M | ¥414M | ¥567M | ¥223M |
| Net Income | ¥198M | ¥311M | ¥386M | ¥156M |
| EPS | ¥19.33 | ¥30.35 | ¥37.67 | ¥15.44 |
| Operating Margin | 14.23% | 16.68% | 15.62% | 7.21% |
| Balance Sheet | ||||
| Total Assets | ¥5,812M | ¥6,543M | ¥7,501M | ¥8,125M |
| Total Equity | ¥2,299M | ¥2,693M | ¥2,628M | ¥2,682M |
| Total Liabilities | ¥3,513M | ¥3,850M | ¥4,873M | ¥5,443M |
| Cash | ¥3,324M | ¥2,846M | ¥3,201M | ¥2,834M |
| Interest-bearing Debt | ¥6M | ¥9M | ¥519M | ¥474M |
| Equity Ratio | 39.55% | 41.15% | 35.03% | 33.01% |
| D/E Ratio | 0.00 | 0.00 | 0.20 | 0.18 |
| Cash Flow | ||||
| Operating CF | ¥100M | ¥335M | ¥468M | ¥74M |
| Investing CF | -¥285M | -¥812M | -¥259M | -¥745M |
| Financing CF | -¥1M | -¥1M | ¥147M | ¥232M |
| Free CF | ¥40M | ¥133M | -¥107M | -¥453M |
| Efficiency | ||||
| ROE | 8.62% | 11.55% | 14.68% | 5.81% |
| ROA | 3.41% | 4.75% | 5.14% | 1.92% |
Latest IR Information
-
Notice Regarding the Issuance of Stock Options
Discloses matters regarding the issuance of stock options. Includes items such as exercise period, number of shares allocated, issue price, and conditions for exercising, with emphasis on future issuance plans and potential shareholder impact. Specific amounts are not disclosed.
Read more -
Financial Summary for the First Quarter of the Fiscal Year Ending March 2027 [Japanese GAAP] (Consolidated)
Discloses the consolidated results for the first quarter of the fiscal year ending March 2027. Provides trends in revenue and profits, segment-by-segment status, and changes in financial position. The accounting period is from April 1, 2026 to June 30, 2026;...
Read more -
Financial Summary / First Quarter of FY2027 P/L Summary (Consolidated)
Public release of the consolidated first quarter P/L summary for FY2027. Highlights include the main indicators such as net sales, operating income, and net income, with YoY comparisons and domestic/overseas breakdown. The outlook and full-year guidance are summarized on a...
Read more -
[Stem Cell Research Institute] Stock Option Issuance | July 22, 2026
Stem Cell Research Institute Co., Ltd. issued a total of 1,564 new stock acquisition rights to directors on July 22, 2026, corresponding to approximately 156,400 shares. The purpose is to enhance performance and secure human resources.
Read more
Latest News (5 items)
Company Information
About
StemCell Institute Inc. engages in the stem cell banking business in Japan. The company is involved in Cell management and transportation services; extraction, purification, processing, storage, testing, and sale of components derived from biological tissues; research, and development, and dissemination of cell-based therapies. Its also offers the manufacturing, wholesale distribution, and sale of pharmaceuticals and medical devices. In addition, the company operates and manages medical facilities, conducts real estate leasing and property management activities, and provides information processing, information, and advertising services, as well as business control and management functions to support its overall operations and affiliated business activities. StemCell Institute Inc. was incorporated in 1999 and is headquartered in Tokyo, Japan. StemCell Institute Inc. is a subsidiary of Trim Medical Holdings Inc.
